By Ginika Igboke
Vinay Prasad, the top vaccine regulator at the U.S. Food and Drug Administration, has exited the agency for a second time, with his last day recorded as April 30. His departure leaves a key leadership gap at a critical moment for vaccine and biologics oversight.
Stepping into the role on an acting basis is Katherine Szarama, formerly the deputy director of the Center for Biologics Evaluation and Research (CBER).
Leadership Transition at a Key FDA Division
CBER, a central division within the U.S. Food and Drug Administration, is responsible for reviewing and regulating vaccines, gene therapies, and other biological products. Its decisions play a major role in determining whether new treatments reach the public.
A spokesperson for the U.S. Department of Health and Human Services confirmed Szarama’s promotion following Prasad’s departure.
Tracy Beth Hoeg, an acting director at another FDA center, publicly praised Prasad’s contributions, describing his tenure as “transformational.”
A Controversial Tenure
Prasad, a professor at the University of California San Francisco, rose to national prominence during the COVID-19 pandemic for his criticism of certain public health policies, including broad vaccination recommendations for younger populations.
He was initially appointed to an FDA leadership role in 2025 by Commissioner Marty Makary, following the resignation of Peter Marks amid disagreements with Health Secretary Robert F. Kennedy Jr..
Prasad briefly left the agency after scrutiny over past social media posts but later returned in August 2025 after Makary intervened, emphasizing the importance of maintaining focus on the FDA’s work.
Policy Scrutiny and Drug Approval Debates
CBER’s recent decisions have drawn criticism from lawmakers across party lines. Ron Johnson has been vocal about the FDA’s handling of treatments for rare diseases, particularly its decision not to approve ataluren for Duchenne muscular dystrophy.
Other critics have questioned the agency’s rejection of a skin cancer treatment developed by Replimune.
Kennedy has defended the FDA’s independence in these decisions, stating that the agency’s conclusions are based on scientific evaluation.
“This decision comes out of FDA and we trust the process there,” he said during an April Senate appearance.
What Comes Next
With Szarama now leading CBER in an acting capacity, attention will turn to how the agency navigates ongoing regulatory challenges, including vaccine oversight, emerging therapies, and political scrutiny.
The leadership shift underscores the complex environment surrounding public health regulation, where scientific judgment, political dynamics, and public trust continue to intersect.
Original article
Comments